Clinical course of multiple sclerosis-associated uveitis: a retrospective series of 49 cases

Résumé fourni par la source

Abstract Background The temporal relationship between uveitis and neurological relapses in multiple sclerosis (MS)–associated uveitis is poorly documented; and MS-targeted disease-modifying therapies (DMTs) may influence the ocular course. Objective To evaluate the temporal relationship between uveitis and neurological relapses in MS-associated uveitis, and to assess the impact of MS treatments on uveitis outcomes. Methods This is a retrospective multicenter study. Uveitis cases were identified from the “Lyon Uvéite” cohort, EDMUS (European Database for Multiple Sclerosis), and open calls for case reporting. Inclusion criteria were: age ≥ 18 years, MS according to McDonald criteria, and uveitis confirmed by an ophthalmologist. Uveitis and neurological flares were considered concomitant if they occurred within a three-month interval. The probability of uveitis relapse was compared between MS-targeted DMTs and uveitis-directed therapies using Kaplan–Meier survival analysis. Results 49 patients were included, with a median follow-up of 19 years [10–25]. Uveitis and neurological relapses were dissociated in 94.2% of cases. In recurrent-event analyses accounting for time-varying treatment exposure, MS-targeted disease-modifying therapies were associated with a lower risk of uveitis relapse compared with uveitis-directed therapies (adjusted HR 0.20, 95% CI [0.08–0.54], p = 0.002). Conclusions MS-associated uveitis appeared largely dissociated from neurological disease activity. MS-targeted disease-modifying therapies were associated with fewer uveitis relapses, although these exploratory findings require confirmation in prospective studies.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.